.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
McKinsey
QuintilesIMS
Cantor Fitzgerald
Colorcon
US Department of Justice
US Army
Fuji
Chinese Patent Office
Fish and Richardson

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,320,968

« Back to Dashboard

Which drugs does patent 7,320,968 protect, and when does it expire?


Patent 7,320,968 protects TESTIM and is included in one NDA. There has been one Paragraph IV challenge on Testim.

This patent has forty-five patent family members in twenty-nine countries.

Summary for Patent: 7,320,968

Title:Pharmaceutical composition
Abstract:A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
Inventor(s): Gyurik; Robert J. (Exeter, NH)
Assignee: Bentley Pharmaceuticals, Inc. (Exeter, NH)
Application Number:10/473,724
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Auxilium Pharms Llc
TESTIM
testosterone
GEL;TRANSDERMAL021454-001Oct 31, 2002AB2RXYesYes► Subscribe► Subscribe METHOD FOR ADMINISTRATION OF TESTOSTERONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,320,968

PCT Information
PCT FiledApril 21, 2003PCT Application Number:PCT/US03/12235
PCT Publication Date:October 30, 2003PCT Publication Number: WO03/088974

Non-Orange Book Patents for Patent: 7,320,968

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,608,605Pharmaceutical composition► Subscribe
7,608,608Pharmaceutical composition► Subscribe
7,608,609Pharmaceutical composition► Subscribe
8,063,029Pharmaceutical composition► Subscribe
7,935,690Pharmaceutical composition► Subscribe
8,178,518Pharmaceutical composition► Subscribe
7,608,610Pharmaceutical composition► Subscribe
7,608,607Pharmaceutical composition► Subscribe
7,608,606Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,320,968

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Iceland2946► Subscribe
Japan2005519985► Subscribe
South Korea20050011753► Subscribe
South Korea100952786► Subscribe
South Korea20090079266► Subscribe
South Korea100977896► Subscribe
Lithuania2004101► Subscribe
Lithuania5235► Subscribe
Eurasian Patent Organization009839► Subscribe
Egypt24882► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Johnson and Johnson
Deloitte
McKesson
Dow
McKinsey
Colorcon
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot